Download MendeleyDesign, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
Shao, M., Chen, X., Yang, F., Song, X., Zhou, Y., Lin, Q., Fu, Y., Ortega, R., Lin, X., Tu, Z., Patterson, A.V., Smaill, J.B., Chen, Y., Lu, X.(2022) J Med Chem 65: 5113-5133
- PubMed: 35271262
- DOI: https://doi.org/10.1021/acs.jmedchem.2c00096
- Primary Citation of Related Structures:
7WCT, 7WCW, 7WCX - PubMed Abstract:
Aberrant FGF19/FGFR4 signaling has been shown to be an oncogenic driver of growth and survival in human hepatocellular carcinoma (HCC) with several pan-FGFR inhibitors and FGFR4-selective inhibitors currently being evaluated in the clinic. However, FGFR4 gatekeeper mutation induced acquired resistance remains an unmet clinical challenge for HCC treatment. Thus, a series of aminoindazole derivatives were designed and synthesized as new irreversible inhibitors of wild-type and gatekeeper mutant FGFR4. One representative compound ( 7v ) exhibited excellent potency against FGFR4, FGFR4 V550L , and FGFR4 V550M with nanomolar activity in both the biochemical and cellular assays while sparing FGFR1/2/3. While compound 7v demonstrated modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model consistent with its unfavorable pharmacokinetic properties, it provides a promising new starting point for future drug discovery combating FGFR4 gatekeeper mediated resistance in HCC patients.
Organizational Affiliation:
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China.
